10/22/2015 | PP | Market Commentary: Intel’s 2.95% convertible sees outright sellers; Proofpoint sees better buyers on earnings
|
10/22/2015 | CV | Market Commentary: Intel’s 2.95% convertible sees outright sellers; Proofpoint sees better buyers on earnings
|
10/20/2009 | CV | Sepracor plans to hold change-of-control offer for convertibles
|
10/20/2009 | SS | Sepracor acquired by Dainippon Sumitomo in $23-per-share deal
|
10/7/2009 | SS | Gabelli, Gamco build 5.93% stake in Sepracor ahead of Dainippon merger
|
9/24/2009 | SS | Sepracor, Dainippon Sumitomo merger clears waiting period hurdle
|
9/3/2009 | CV | Market Commentary: Sepracor adds on takeout news; Terex, Newmont rise with shares; NetApp weakens on tepid demand
|
9/3/2009 | SS | Dainippon Sumitomo to buy Sepracor in $23-per-share cash tender offer
|
9/3/2009 | SS | Market Commentary: Market concerns crowd Sun buyout; investors mull Sepracor bid; regulators could delay BJ deal
|
8/5/2009 | CV | Sepracor buys $48.2 million of its zero-coupon notes for $43.8 million
|
3/17/2009 | CV | Sepracor holders tender $143.45 million 0% convertibles due 2024
|
2/17/2009 | CV | Sepracor begins tender offer for 0% convertibles due 2024
|
11/19/2008 | CV | Market Commentary: Ford falls as rescue hopes dim; Chesapeake, Transocean, Prudential see strength; Sepracor trading picks up
|
8/11/2008 | CV | Sepracor buys back $21.3 million of its 0% convertibles due 2024
|
7/3/2007 | CV | June convertibles returns down after credit spreads rise, stock market falls, Citi says
|
4/25/2007 | SS | Market Commentary: Chaparral rises; K2 higher; Delta on tap; Wendy's up; Alcoa firms; Sepracor spikes; Bally up on sale
|
2/27/2007 | SP | New Issue: Barclays sells $1.5 million 11% reverse convertibles linked to Sepracor
|
2/6/2007 | SP | Barclays to price 11% reverse convertibles linked to Sepracor
|
10/26/2006 | BT | Sepracor ends quarter with $997.2 million in cash, investments
|
8/10/2006 | BT | Sepracor delays filing of quarterly report due to internal review of stock options; to restate results
|
7/21/2006 | BT | Sepracor second-quarter revenues up at $264.4 million, six-month revenues rise to $550.1 million
|
6/29/2006 | CV | Market Commentary: Red Hat rises dollar-neutral, falls outright; new Vector bid higher; CNET, Intel gain; Nexans prices deal
|
6/21/2006 | BT | Sepracor study compares Lunesta effectiveness among ethnic groups
|
6/5/2006 | CV | Market Commentary: SanDisk gains outright on stock upgrade; Sepracor falls on probe; Interpublic plans unique deal
|
5/25/2006 | BT | Sepracor: Lunesta sleep benefits minimize rheumatoid arthritis, menopause symptoms
|
5/24/2006 | BT | Sepracor reports two studies show arformoterol helps in chronic obstructive pulmonary disease
|
5/16/2006 | BT | Market Commentary: Neurocrine, DOV dive; Novavax, Generex dive amid noise of exits; Adventrx slips modestly on deal
|
5/16/2006 | CV | Market Commentary: American Axle surges on possible loophole; DOV Pharmaceuticals falls, Sepracor gains on drug's rejection
|
5/15/2006 | BT | Market Commentary: BioMimetic goes south; Sirna off on new deal; Cambridge rockets on buyout; Threshold extends fall
|
5/12/2006 | BTCV | New Issue: Merrill Lynch prices $15 million 3% capped appreciation notes linked to biotech stock basket
|
4/26/2006 | BT | Citigroup reiterates Sepracor at buy
|
4/25/2006 | BT | Sepracor Q1 revenue boosted to $285.7 million by Lunesta sales
|
4/19/2006 | BT | Citigroup puts Sepracor at buy
|
4/4/2006 | BT | Sepracor says Lunesta may relieve symptoms in major depressive disorder
|
3/28/2006 | BT | Sepracor at buy by Citigroup
|
2/23/2006 | BT | Sepracor licenses antihistamine patents to UCB
|
2/13/2006 | BTCV | S&P upgrades Sepracor
|
1/31/2006 | BT | Market Commentary: Nuvelo zooms after deal; SGX cuts guidance, prices at low end; Sepracor soars; BioMarin bounces
|
1/31/2006 | BT | Sepracor sees black for first time in 2005, revenues reach $820.9 million
|
1/31/2006 | CV | Market Commentary: Earnings send Sepracor higher, but UnumProvident, Goodyear lower; Huntsman adds on takeout talk
|
1/26/2006 | BT | Citigroup reiterates Sepracor at buy
|
1/17/2006 | BT | Market Commentary: Arena gains in face of follow-on deal; deCODE spikes on diabetes discovery; Acadia, Sepracor firm
|
1/12/2006 | BT | Sepracor prepared to defend patent rights for Xopenex
|
1/11/2006 | BT | Citigroup reiterates Sepracor at buy/high risk
|
11/8/2005 | BT | Sepracor to buy back stock used to settle call spread options
|
11/7/2005 | CV | Market Commentary: Northwest, AMR higher as oil declines; Genzyme eases but Cephalon edges higher
|
11/3/2005 | BT | Sepracor's Xopenex data show improved lung function
|
10/26/2005 | BT | Citigroup keeps Sepracor at buy
|
10/25/2005 | BT | Market Commentary: Indevus spikes on trial; Idenix off big on follow-on sale; Rigel up on Serono pact; Sepracor rises
|
10/25/2005 | CV | Market Commentary: Sovereign slides, Schlumberger, Sepracor lift; Essex reoffered at 98; Flextronics drops after close
|
10/21/2005 | BT | Citigroup reiterates Sepracor at buy
|
10/19/2005 | BT | Sepracor starts Phase I study for depression drug
|
9/20/2005 | CV | Market Commentary: US Airways, Toreador launch new deals, bringing calendar to five; Sepracor, Cephalon up
|
9/9/2005 | BT | Sepracor upgraded by Smith Barney to buy
|
9/9/2005 | BT | Market Commentary: Genomic talk surfaces; Voyager files IPO; Elan joins Biogen fall on restructuring; Sepracor lifted
|
9/8/2005 | BT | Sepracor reiterated by Smith Barney at hold
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
7/20/2005 | BT | Sepracor estimates lowered by Smith Barney
|
7/18/2005 | CV | Market Commentary: Convertibles market pauses ahead of earnings; Genzyme falls amid mixed biotechs, Lucent, financials ease
|
7/15/2005 | BT | Sepracor estimates raised by Smith Barney
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/7/2005 | BT | Market Commentary: Accentia delays IPO on positive news; Salix takes off; Millipore gains; Sepracor off; Amgen soars
|
4/25/2005 | CV | Market Commentary: Merger news pushes DoubleClick, Valero higher; Calpine continues slide; Sepracor 0s up, 5s decline
|
2/18/2005 | CV | Market Commentary: Lions Gate, BlackRock, Sybase weak; Sepracor's older convertibles bleed; Fannie credit holding up
|
2/17/2005 | CV | Market Commentary: BlackRock lifted; Lions Gate rolls out; Sepracor arbs hurt; REITs hit; Royal Caribbean call risk allayed
|
2/9/2005 | CV | Market Commentary: Protein Design Labs sweetened, sinks; Huntsman hotly pursued; Allergan, Sepracor off, Saks up
|
10/18/2004 | CV | Sepracor extends greenshoe exercise deadline
|
10/15/2004 | CV | Top volatility plays: BankUnited, Schlumberger, Teva, HCC Insurance, Quanex, Merrill says
|
9/20/2004 | CV | Market Commentary: Beazer, Lennar drop; Novell overtaking Red Hat as Linux pick; Delta, airlines ease back
|
9/17/2004 | CV | New Issue: Sepracor sells $500 million convertibles at 0%, up 30%
|
9/17/2004 | CVDD | S&P rates Sepracor convertibles CCC+
|
9/17/2004 | CV | Market Commentary: Sepracor issue straddles par; Vitesse goes to 103; EDS firm despite warning; biotechs rally
|
9/16/2004 | CV | Sepracor $500 million overnight convertible talked to yield 0%, up 26%-34%
|
9/16/2004 | CV | Market Commentary: Sepracor, Vitesse deals emerge; Delta converts steady; Nortel, Lucent tumble; Providian better
|
9/10/2004 | CV | Sepracor exchanges further $25 million convertibles for stock and cash
|
9/7/2004 | CVDD | S&P: Sepracor unaffected
|
9/3/2004 | CV | Sepracor exchanges $504 million 0% convertibles for stock, cash
|
7/26/2004 | CV | Market Commentary: King Pharma soars on merger; Boise Cascade higher on split; Marshall & Ilsley deal emerges
|
6/7/2004 | CV | Market Commentary: Mandalay event sparks furor on concern about no cash takeover protection; 20-30 names suffer
|
3/26/2004 | CVDD | S&P: Sepracor unaffected
|
3/2/2004 | CV | Market Commentary: Avnet, Bell Micro gain; Amdocs slips; in gray, PSS bid plus 1 point, First Horizon at plus 0.25 point
|
3/1/2004 | CV | Market Commentary: Sepracor news wakes a raging bidding war in converts; 4 new deals emerge, including Amdocs
|
3/1/2004 | CVDD | S&P: Sepracor outlook positive
|
1/12/2004 | CV | Sepracor greenshoe exercised, raising convertibles to $750 million
|
1/8/2004 | CV | Sepracor extends greenshoe exercise deadline
|
1/7/2004 | CV | Market Commentary: Coeur d'Alene bid up 1 point in gray market; Red Hat hits 103.25 bid; Duke rebounds
|
12/15/2003 | CV | Sepracor calls 5.75% convertibles
|
12/10/2003 | CV | Market Commentary: Magnum, Scottish Re, CenterPoint emerge; Emulex, Akamai decline; Wyeth bid 0.5 over par in gray
|
12/10/2003 | CVDD | S&P rates new Sepracor convertible CCC+
|
12/9/2003 | CV | Market Commentary: Another $2.575 billion of deals; Akamai, Emulex both reoffered at 98
|
12/9/2003 | CV | New Issue: Sepracor $200 million convert at 0%, up 24%, $400 million convert at 0%, up 16%
|
12/9/2003 | CVDD | S&P rates new Sepracor convertibles CCC
|
12/8/2003 | CV | Sepracor to sell $200 million convertible at 0%, up 24-32%; $400 million convert at 0%, up 16-24%
|
12/8/2003 | CV | Market Commentary: Issuers unwrap $1.73 billion of new paper and more set to come this week, this month
|
12/3/2003 | CV | S&P: Sepracor ratings unaffected by drug news
|
6/3/2003 | CV | Market Commentary: Mirant 5.75s fall 12-15 points on bankruptcy buzz; six new deals afloat in primary
|
6/3/2003 | CV | Valassis buys back $185.3 million 0% convertibles with proceeds of new deal
|
1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
9/24/2002 | CV | Sepracor buys back $131.1 million 7% convertibles
|
4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
4/5/2002 | CV | Salomon: Shrinking premiums, rising delta signal times to shift positions
|
3/21/2002 | CV | Convertibles gain as buyers emerge, PDLI clips slide
|
3/19/2002 | CV | Salomon analyst: Buy Sepracor 7% convertibles on weakness
|
3/15/2002 | CV | Market Commentary: Convertibles edge up, quiet after busy week of new deals
|
3/8/2002 | CV | Market Commentary: Convertibles gain on Nasdaq strength; Alpharma drops
|
3/7/2002 | CV | Market Commentary: Convertibles stall with stocks; oils, financials gain
|
3/7/2002 | CV | Sepracor explodes on surprise setback from FDA on new drug
|
2/4/2002 | CV | Market Commentary: Convertibles plunge as stocks dive, Solutia nixes new deal
|
1/3/2002 | CV | Moody's puts Xerox on review for downgrade
|
12/24/2001 | CV | Market Commentary: Convertibles mixed, flat on light volume in holiday-shortened session
|
12/21/2001 | CV | Sepracor says greenshoe exercised, raising convertibles to $500 million
|
11/27/2001 | CV | Market Commentary: Convertible market seen flat on heavy trading from high volatility
|
11/8/2001 | CV | Market Commentary: Convertible market ends flat, new deals getting richer
|
11/8/2001 | CV | New Issue: Sepracor sells $400 million convertibles at 5.75% yield, up 24.7%
|
11/7/2001 | CV | Market Commentary: Convertible market gains with spate of new deals
|